NO2525798T3 - - Google Patents

Info

Publication number
NO2525798T3
NO2525798T3 NO11734245A NO11734245A NO2525798T3 NO 2525798 T3 NO2525798 T3 NO 2525798T3 NO 11734245 A NO11734245 A NO 11734245A NO 11734245 A NO11734245 A NO 11734245A NO 2525798 T3 NO2525798 T3 NO 2525798T3
Authority
NO
Norway
Application number
NO11734245A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2525798T3 publication Critical patent/NO2525798T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO11734245A 2010-01-21 2011-01-19 NO2525798T3 (h)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US38531810P 2010-09-22 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (1)

Publication Number Publication Date
NO2525798T3 true NO2525798T3 (h) 2018-01-06

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11734245A NO2525798T3 (h) 2010-01-21 2011-01-19

Country Status (27)

Country Link
US (2) US8697678B2 (h)
EP (1) EP2525798B1 (h)
JP (1) JP5930311B2 (h)
KR (1) KR101747476B1 (h)
CN (1) CN102802635B (h)
AU (1) AU2011207103B2 (h)
BR (1) BR112012017800B1 (h)
CA (1) CA2786762C (h)
CL (1) CL2012002032A1 (h)
CY (1) CY1119947T1 (h)
DK (1) DK2525798T3 (h)
ES (1) ES2646829T3 (h)
GB (2) GB2484244B (h)
HR (1) HRP20171699T1 (h)
HU (1) HUE035441T2 (h)
LT (1) LT2525798T (h)
NO (1) NO2525798T3 (h)
NZ (1) NZ601255A (h)
PL (1) PL2525798T3 (h)
PT (1) PT2525798T (h)
RS (1) RS56576B1 (h)
RU (1) RU2574022C2 (h)
SG (1) SG181997A1 (h)
SI (1) SI2525798T1 (h)
SM (1) SMT201700518T1 (h)
WO (1) WO2011088503A1 (h)
ZA (1) ZA201205370B (h)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5334588B2 (ja) 2005-11-28 2013-11-06 マリナス ファーマシューティカルズ ガナキソロン製剤、およびその作製方法、およびその使用
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
ES2784629T3 (es) * 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
MX2014008895A (es) * 2012-01-23 2014-11-25 Sage Therapeutics Inc Formulaciones de esteroides neuroactivos y metodos para tratar trastornos del cns.
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL294306B2 (en) * 2012-08-21 2024-01-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2916846B1 (en) * 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
WO2014085668A1 (en) * 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN115381772A (zh) * 2015-02-06 2022-11-25 马瑞纳斯制药公司 静脉内加奈索酮制剂及其用途
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
AU2016338672A1 (en) * 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN111971238B (zh) 2018-04-16 2022-02-18 川崎重工业株式会社 带式输送机
US11472833B2 (en) 2018-07-03 2022-10-18 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3123002A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399716B1 (en) * 1989-05-24 1994-01-26 Innovet, Inc. Hypoallergenic steroidal anesthetic/hypnotic compositions
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
JP5334588B2 (ja) * 2005-11-28 2013-11-06 マリナス ファーマシューティカルズ ガナキソロン製剤、およびその作製方法、およびその使用

Also Published As

Publication number Publication date
CY1119947T1 (el) 2018-12-12
ES2646829T3 (es) 2017-12-18
KR101747476B1 (ko) 2017-06-14
BR112012017800B1 (pt) 2020-12-08
SG181997A1 (en) 2012-08-30
EP2525798B1 (en) 2017-08-09
CN102802635B (zh) 2014-07-30
US8975245B2 (en) 2015-03-10
EP2525798A1 (en) 2012-11-28
GB2491491A (en) 2012-12-05
GB201210657D0 (en) 2012-08-01
GB2484244B (en) 2012-10-31
EP2525798A4 (en) 2014-02-19
PL2525798T3 (pl) 2018-05-30
BR112012017800A2 (pt) 2018-07-10
BR112012017800A8 (pt) 2018-08-14
SI2525798T1 (en) 2018-01-31
WO2011088503A1 (en) 2011-07-28
US20120316146A1 (en) 2012-12-13
PT2525798T (pt) 2017-11-15
JP2013517299A (ja) 2013-05-16
CL2012002032A1 (es) 2012-12-21
JP5930311B2 (ja) 2016-06-08
HUE035441T2 (en) 2018-05-02
RU2574022C2 (ru) 2016-01-27
LT2525798T (lt) 2018-01-10
ZA201205370B (en) 2013-09-25
CN102802635A (zh) 2012-11-28
US20140066417A1 (en) 2014-03-06
AU2011207103B2 (en) 2013-03-21
HK1169031A1 (en) 2013-01-18
DK2525798T3 (da) 2017-11-20
US8697678B2 (en) 2014-04-15
SMT201700518T1 (it) 2018-01-11
KR20120136347A (ko) 2012-12-18
CA2786762A1 (en) 2011-07-28
CA2786762C (en) 2017-12-05
GB2484244A (en) 2012-04-04
RS56576B1 (sr) 2018-02-28
GB201201842D0 (en) 2012-03-21
AU2011207103A1 (en) 2012-07-26
HRP20171699T1 (hr) 2018-01-26
GB2491491B (en) 2014-07-30
NZ601255A (en) 2013-09-27
RU2012134321A (ru) 2014-02-27

Similar Documents

Publication Publication Date Title
BR112013008959A2 (h)
BR112012031500A2 (h)
BR112012029986A2 (h)
BR112012030039A2 (h)
BR112012028408A2 (h)
BR112012026492A2 (h)
BR112012027808A2 (h)
BR112012024897A2 (h)
BR112012019354A2 (h)
BR112012025307A2 (h)
BR112012017960A2 (h)
BR112012026946A2 (h)
BR112012025482A2 (h)
BR112013006400A2 (h)
BR112012031826A2 (h)
BR112012023249A2 (h)
BR112012028186A2 (h)
BR112012025577A2 (h)
BR112012016456A2 (h)
NO2525798T3 (h)
BR112012018256A2 (h)
BR112012027015A2 (h)
BR112012025308A2 (h)
BR112012027945A2 (h)
BR112012024872A2 (h)